- The U.S. Supreme Court has denied the petition for a writ of certiorari (orders a lower court to deliver its record in a case so the higher court may review it) from a subsidiary of Hikma Pharmaceuticals related to U.S. Patent No. 8,586,610 covering Vanda Pharmaceuticals' (VNDA -5.2%) Fanapt (iloperidone) tablets.
- The denial means that the patent will remain in effect through November 2, 2027 (unless successfully challenged beforehand).
Vanda Pharma prevails in Fanapt patent challenge
Recommended For You
About VNDA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VNDA | - | - |
Vanda Pharmaceuticals Inc. |